Prognostic implications of DPP‐4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting – results of the 1 year follow‐up of the prospective DiaRegis registry

ConclusionsThe present results confirm prior randomised controlled trial results in patients with type 2 diabetes from real world clinical practice demonstrating that DPP4‐I on top of prior metformin monotherapy result in similar HbA1c reductions within 12 months but a significant reduction in hypoglycaemia compared with sulfonylurea added to metformin. The reduction in vascular events observed has to be verified in larger cohorts.

Source: International Journal of Clinical Practice - August 28, 2013 Category: Internal Medicine Authors: A. K. Gitt, P. Bramlage, C. Binz, M. Krekler, E. Deeg, D. Tschöpe Tags: Original Paper Source Type: research